Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6NSCLC 5Respiratory Tract Neoplasms 1Lung Neoplasms 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1Advanced Lung Cancer 1

Interventions

aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced NSCLC Patients With T790M × aflutinib × Clear all
NCT03452592 2025-04-03

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Allist Pharmaceuticals, Inc.

Phase 2 Terminated
220 enrolled
Thoracic

Advanced NSCLC Patients With T790M

Data powered by HemOnc (CC BY 4.0) Colophon âš¡